Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viking Therapeutics (VKTX – Research Report) and Bristol-Myers Squibb (BMY – Research Report).

Viking Therapeutics (VKTX)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics, with a price target of $120.00. The company’s shares closed last Thursday at $68.86.

According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.0% and a 30.8% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Virpax Pharmaceuticals, and Petros Pharmaceuticals.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $113.50, an 80.2% upside from current levels. In a report issued on April 24, Leerink Partners also reiterated a Buy rating on the stock with a $115.00 price target.

See today’s best-performing stocks on TipRanks >>

Bristol-Myers Squibb (BMY)

In a report released yesterday, Evan Seigerman from BMO Capital assigned a Hold rating to Bristol-Myers Squibb, with a price target of $48.00. The company’s shares closed last Thursday at $44.70, close to its 52-week low of $44.37.

According to TipRanks.com, Seigerman is a 3-star analyst with an average return of 2.2% and a 42.4% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and AbCellera Biologics.

Currently, the analyst consensus on Bristol-Myers Squibb is a Hold with an average price target of $53.36, implying a 12.6% upside from current levels. In a report issued on April 10, Leerink Partners also maintained a Hold rating on the stock with a $51.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VKTX:

• Viking Therapeutics reports Q1 EPS (26c), consensus (28c)
• Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
• Viking Therapeutics options imply 8.8% move in share price post-earnings
• Viking Therapeutics management to meet virtually with Truist
• VKTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?